JP2013100370A5 - - Google Patents

Download PDF

Info

Publication number
JP2013100370A5
JP2013100370A5 JP2013040387A JP2013040387A JP2013100370A5 JP 2013100370 A5 JP2013100370 A5 JP 2013100370A5 JP 2013040387 A JP2013040387 A JP 2013040387A JP 2013040387 A JP2013040387 A JP 2013040387A JP 2013100370 A5 JP2013100370 A5 JP 2013100370A5
Authority
JP
Japan
Prior art keywords
composition
cancer cells
cancer
cancer cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013040387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013100370A (ja
JP5665899B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013100370A publication Critical patent/JP2013100370A/ja
Publication of JP2013100370A5 publication Critical patent/JP2013100370A5/ja
Application granted granted Critical
Publication of JP5665899B2 publication Critical patent/JP5665899B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013040387A 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体 Expired - Fee Related JP5665899B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80364006P 2006-06-01 2006-06-01
US60/803,640 2006-06-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009513472A Division JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014248831A Division JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体

Publications (3)

Publication Number Publication Date
JP2013100370A JP2013100370A (ja) 2013-05-23
JP2013100370A5 true JP2013100370A5 (enExample) 2013-11-07
JP5665899B2 JP5665899B2 (ja) 2015-02-04

Family

ID=38802246

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009513472A Withdrawn JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体
JP2013040387A Expired - Fee Related JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体
JP2014248831A Pending JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009513472A Withdrawn JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014248831A Pending JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Country Status (12)

Country Link
US (3) US8512713B2 (enExample)
EP (3) EP3254694A1 (enExample)
JP (4) JP2009538935A (enExample)
KR (1) KR20090014364A (enExample)
CN (1) CN101460194B (enExample)
AU (1) AU2007256754B2 (enExample)
CA (2) CA2652228C (enExample)
IL (1) IL195297A (enExample)
MX (1) MX2008015265A (enExample)
NZ (1) NZ572893A (enExample)
WO (1) WO2007143548A2 (enExample)
ZA (1) ZA200809769B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
FR2946536B1 (fr) * 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
EP3846829A4 (en) * 2018-09-05 2022-09-14 Arizona Board of Regents on behalf of Arizona State University ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1200595A2 (en) 1999-07-12 2002-05-02 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
WO2001087324A1 (en) 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
US7582614B2 (en) * 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
DK2388315T3 (da) * 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2007147118A1 (en) 2006-06-16 2007-12-21 Robarts Research Institute Infection of cells with myxoma virus requires akt activation

Similar Documents

Publication Publication Date Title
IL287381A (en) Pharmaceutical preparations of human rpe cells and uses thereof
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
JP2014141525A5 (enExample)
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
HUE036220T2 (hu) Kinazolin származékok vírusfertõzések és további betegségek kezelésére
EA201500314A1 (ru) Лекарственные формы энзалутамида
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
NZ606765A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
JP2013100370A5 (enExample)
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
CO7030958A2 (es) Compuestos sustituidos de bencilamina, su uso en medicina, y en particular en el tratamiento de la infección del virús de la hepatitis c (vch)
JP2015044878A5 (enExample)
IL222343B (en) Compositions comprising allogeneic th1 cells and inf-gamma for treating cancer or infectious diseases